| Metric | Value (₹ Cr) | vs Q4 FY25 |
|---|---|---|
| Revenue | 1.9K | 1.5% |
| Total Income | 1.9K | 1.4% |
| Expenditure | 1.8K | 1.6% |
| PBT | 154.50 | 25.0% |
| Net Profit | 102.50 | 32.3% |
| OPM | 15.24% | 2.50pp |
| NPM | 5.36% | 2.44pp |
| EPS | 6.49 | 33.2% |
Jubilant Pharmova Reports Q1’FY26 Results: 10% Revenue Growth, EBITDA & PAT Margin Expansion
29 Jul 2025 · 29 Jul 2025, 02:04 pm
Summary
Jubilant Pharmova Limited reported its Q1’FY26 results with a 10% revenue growth, EBITDA margin expansion, and PAT margin expansion. The company saw solid growth momentum across all business units, with particular strength in the CDMO Sterile Injectable business. The company is investing in future growth through increased capex intensity, and expects to see continued growth in the Radiopharma, CDMO Sterile Injectables, and CRDMO businesses.
Key Highlights
- 1
Revenue grew by 10% to Rs. 1,901 Cr.
- 2
EBITDA grew by 14% to Rs. 302 Cr.
- 3
Normalised PAT grew by 48% to Rs. 103 Cr.
- 4
Radiopharmaceuticals Q1’FY26 revenue grew by 3% to Rs. 271 Cr.
- 5
Radiopharmacy Q1’FY26 revenue grew by 5% YoY to Rs. 598 Cr.
- 6
Allergy Immunotherapy Q1’FY26 revenues grew by 8% to Rs. 181 Cr.
- 7
CDMO Sterile Injectables Q1’FY26 revenue grew by 14% to Rs. 370 Cr.
Management Comments
Mr. Shyam S Bhartia
We are pleased to announce revenue of Rs. 1,901 Cr. in Q1’FY26, growth of 10% over last year, same quarter. It is heartening to note is that we delivered solid revenue growth across all of our business units and we expect this growth momentum to grow stronger as we move forward.
Informational and educational content only. Not investment advice.